ClearOne is trading 5.3% down at $6.25 amid continued volatility following its recently announced reverse merger with Vivani Medical’s Cortigent unit.
- The stock has swung sharply since early July, including a more than 170% surge after the merger news and further gains tied to optimism about the brain-computer interface deal.
- Subsequent pullbacks likely reflect profit-taking and dilution concerns following the massive rally.